News and Announcements
EDITORIAL
Targeting α-synuclein in Parkinson’s disease and Lewy Body Disorders: A new era of precision medicine
Show Less
1 Department of Neurology, University Hospital Policlinico “G. Rodolico-San Marco,” Catania,
Italy
Advanced Neurology, 026210021 https://doi.org/10.36922/AN026210021
Received: 19 May 2026 | Published online: 28 May 2026
(This article belongs to the Special Issue Targeting α-Synuclein in Parkinson's Disease and Lewy Body Disorders)
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Conflict of interest
Giorgia Sciacca serves on the Youth Editorial Board of this journal and is the sole Guest Editor of this Special Issie. She declares no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
- Outeiro TF, Koss DJ. Nuclear Alpha-Synuclein: Mechanisms and Implications for Synucleinopathies. Mov Disord. 2026;41(3):603–612. doi: 10.1002/mds.70138
- Sekiya H, Jensen NM, Dickson DW, Jensen PH. Seeing Invisible Oligomers: Rethinking alpha-Synuclein Pathology Through Proximity Ligation Assay. Mov Disord. 2026. doi: 10.1002/mds.70335
- Grimwade IJH, Enticknap G, De Pablo Fernandez E, Croft CL. alpha-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives. Expert Rev Mol Med. 2026;28:e7. doi: 10.1017/erm.2026.10037
- Tang P, Jing Z, Tong Z, Peng X, Tong J, Peng Y. Unraveling the role of non-coding RNAs in Parkinson’s disease: Molecular mechanisms and therapeutic insights. Int J Biochem Cell Biol. 2026;197–198:106963. doi: 10.1016/j.biocel.2026.106963
- Eijsvogel PPNM, Smits LMG, Kremer PHC, Groeneveld GJ. A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders. Clin Pharmacol Ther. 2026. doi: 10.1002/cpt.70315
- Kaila LV, Ikeda M, Sultana J, Chouliaras L, O’Brien JT, Taylor JP. The evolving therapeutic landscape of dementia with Lewy bodies. Lancet Neurol. 2025;24(12):1038–1052. doi: 10.1016/S1474-4422(25)00323-0
- Pitton Rissardo J, McGarry A, Shi Y, Fornari Caprara AL, Kannarkat GT. Alpha-Synuclein Neurobiology in Parkinson’s Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives. Brain Sci. 2025;15(12):1260. doi: 10.3390/brainsci15121260
- Zhang S, Wang T, Peng Y, et al. Parkinson’s disease: pathogenesis and therapeutic strategies. Mol Biomed. 2026;7(1):46. doi: 10.1186/s43556-026-00445-0